Both companies’ stocks surged Nov. 7 on positive data from a second Phase III trial showing the antisense drug improved motor function in children with later onset spinal muscular atrophy.
With positive data from a second Phase III trial testing Biogen Inc./Ionis Pharmaceuticals Inc.’s Spinraza (nusinersen) in children with spinal muscular atrophy (SMA) now in hand, the antisense drug appears on track to be the first drug approved by FDA for the genetic rare disease, and poised for a broad label.
Biogen is anticipating a rapid approval and said it is preparing to launch Spinraza by the end of the year or early 2017, even though the company only
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Vyepti revenues rise by nearly 70% in the first quarter.
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
Vyepti revenues rise by nearly 70% in the first quarter.
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
